UCB Biosciences Inc.

3 trials 1 recruiting Commercial sponsor

Filter these 3 trials by condition, phase, country and more.

Open in Search →

3 Registered trials

1 Recruiting

1 Completed trials

7 Countries active

3 Unique IMPs

100% Results reported

Phase III

Phase II

Phase III: 2 Phase II: 1

Oversight events:

1 corrective measure across 1 trial

View oversight register →

100%

1 of 1 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Mitochondrial DNA depletion 1 Rett syndrome 1

Top IMPs

FENFLURAMINE HYDROCHLORIDE 2 DOXRIBTIMINE, DOXECITINE 1

All trials

3 total

A study to learn if fenfluramine hydrochloride is safe and works in people with Rett syndrome Pending

2025-523157-34-00 Phase III 7 countries FENFLURAMINE HYDROCHLORIDE
A study to learn how safe fenfluramine is, how well it works, and how it moves through the bloodstream in infants with Dravet syndrome Recruiting

2022-502359-75-00 Phase III 4 countries FENFLURAMINE HYDROCHLORIDE
A study to learn if combination pyrimidine nucleosides is safe, how well it works and how it moves through the bloodstream in participants w… Ended

2023-510427-29-00 Phase II 1 country DOXRIBTIMINE, DOXECITINE

Showing 1–3 of 3 trials

← All sponsors A–Z